AAM
VIVO

ACK Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

ACK Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-139,450
Closed -$2.47M – 33
2016
Q4 		$2.47M Buy
139,450
+4,500
+3% +$79K 0.73% 28
2016
Q3 		$2.6M Buy
+134,950
New +$2.64M 0.79% 29

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

ACK Asset Management's VIVO Position: Q1 2017 in Review

ACK Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2017, closing a stake of 139,450 shares — an estimated $2.47M sold.

ACK Asset Management first reported a position in VIVO in Q3 2016 and held it in 2 quarters. The position peaked at $2.6M in Q3 2016. 165 funds tracked by Wall St. Rank hold VIVO as of Q1 2017.

  • ACK Asset Management reported no remaining Meridian Bioscience Inc position as of Q1 2017 after selling out during the quarter.
  • ACK Asset Management sold 139,450 Meridian Bioscience Inc shares in Q1 2017, an estimated $2.47M.
  • ACK Asset Management first reported a position in Meridian Bioscience Inc in Q3 2016 and held it in 2 quarters.
  • ACK Asset Management's Meridian Bioscience Inc position peaked at $2.6M in Q3 2016.
  • 165 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2017.

Based on ACK Asset Management's 13F filing for Q1 2017, filed 12 May 2017.